Skip to main content
Top
Published in: International Journal of Hematology 4/2018

01-10-2018 | Original Article

Identification of the BRAF V600E mutation in Japanese patients with hairy cell leukemia and related diseases using a quenching probe method

Authors: Hidekazu Itamura, Masaru Ide, Akemi Sato, Naoko Sueoka-Aragane, Eisaburo Sueoka, Aya Nishida, Taro Masunari, Sadao Aoki, Jun Takizawa, Junji Suzumiya, Shinya Kimura

Published in: International Journal of Hematology | Issue 4/2018

Login to get access

Abstract

Hairy cell leukemia (HCL) is a rare B-cell lymphoid malignancy that is difficult to distinguish from other morphological variants. The frequency of HCL has not been determined accurately in Japan. Recent studies revealed that the BRAF V600E mutation is the causal genetic event in HCL. We assessed the BRAF mutation in Japanese patients with HCL and related diseases using the quenching probe (QP) method, a single-nucleotide polymorphism detection system, and evaluated the incidence rate of HCL among Japanese patients with chronic lymphocytic leukemia, and related diseases. We identified 18 cases (33.3%) harboring the BRAF mutation among 54 patients diagnosed with, or suspected of having HCL. Of BRAF V600E-positive patients, 7 were only detected using the QP method, not by direct sequencing, whereas 11 were positive using both tests. In a larger cohort of Japanese patients diagnosed with chronic lymphoid leukemia or related diseases, the frequency of HCL was 4%. Patients with the BRAF V600E mutation had a significantly higher frequency of neutropenia, thrombocytopenia, and elevated soluble interleukin-2 receptor and common B-cell surface markers than patients without the mutation. Our results confirm that BRAF V600E-positive HCL is a relatively rare disorder in the Japanese leukemia patient population.
Appendix
Available only for authorised users
Literature
1.
go back to reference Schrek R, Donnelly WJ. “Hairy” cells in blood in lymphoreticular neoplastic disease and “flagellated” cells of normal lymph nodes. Blood. 1966;27:199–211.PubMed Schrek R, Donnelly WJ. “Hairy” cells in blood in lymphoreticular neoplastic disease and “flagellated” cells of normal lymph nodes. Blood. 1966;27:199–211.PubMed
2.
go back to reference Forconi F. Hairy cell leukaemia: biological and clinical overview from immunogenetic insights. Hematol Oncol. 2011;29:55–66.CrossRefPubMed Forconi F. Hairy cell leukaemia: biological and clinical overview from immunogenetic insights. Hematol Oncol. 2011;29:55–66.CrossRefPubMed
3.
go back to reference Jones G, Parry-Jones N, Wilkins B, Else M, Catovsky D. Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant. Br J Haematol. 2012;156:186–95.CrossRefPubMed Jones G, Parry-Jones N, Wilkins B, Else M, Catovsky D. Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant. Br J Haematol. 2012;156:186–95.CrossRefPubMed
4.
go back to reference Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: World Heal. Organ. Classification Tumours Haematop. Lymphoid Tissue; 2008. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: World Heal. Organ. Classification Tumours Haematop. Lymphoid Tissue; 2008.
5.
go back to reference Bernstein L, Newton P, Ross RK. Epidemiology of hairy cell leukemia in Los Angeles County. Cancer Res. 1990;50:3605–9.PubMed Bernstein L, Newton P, Ross RK. Epidemiology of hairy cell leukemia in Los Angeles County. Cancer Res. 1990;50:3605–9.PubMed
6.
go back to reference Paltiel O, Adler B, Barchana M, Dann EJ. A population-based study of hairy cell leukemia in Israel. Eur J Haematol. 2006;77:372–7.CrossRefPubMed Paltiel O, Adler B, Barchana M, Dann EJ. A population-based study of hairy cell leukemia in Israel. Eur J Haematol. 2006;77:372–7.CrossRefPubMed
7.
go back to reference Cawley JC, Burns GF, Hayhoe FGJ. A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia. Leuk Res. 1980;4:547–59.CrossRefPubMed Cawley JC, Burns GF, Hayhoe FGJ. A chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia. Leuk Res. 1980;4:547–59.CrossRefPubMed
8.
go back to reference Machii T, Tokumine Y, Inoue R, Kitani T. A unique variant of hairy cell leukemia in Japan. Jpn J Med. 1990;29:379–83.CrossRefPubMed Machii T, Tokumine Y, Inoue R, Kitani T. A unique variant of hairy cell leukemia in Japan. Jpn J Med. 1990;29:379–83.CrossRefPubMed
9.
go back to reference Machii T, Tokumine Y, Inoue R, Kitani T. Predominance of a distinct subtype of hairy cell leukemia in Japan. Leukemia. 1993;7:181–6.PubMed Machii T, Tokumine Y, Inoue R, Kitani T. Predominance of a distinct subtype of hairy cell leukemia in Japan. Leukemia. 1993;7:181–6.PubMed
10.
go back to reference Machii T, Yamaguchi M, Inoue R, Tokumine Y, Kuratsune H, Nagai H, et al. Polyclonal B-cell lymphocytosis with features resembling hairy cell leukemia-Japanese variant. Blood. 1997;89:2008.PubMed Machii T, Yamaguchi M, Inoue R, Tokumine Y, Kuratsune H, Nagai H, et al. Polyclonal B-cell lymphocytosis with features resembling hairy cell leukemia-Japanese variant. Blood. 1997;89:2008.PubMed
11.
go back to reference Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.CrossRefPubMedPubMedCentral Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.CrossRefPubMedPubMedCentral
12.
13.
go back to reference Chung SS, Kim E, Park JH, Chung YR, Lito P, Teruya-Feldstein J, et al. Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Sci Transl Med. 2014;6:238ra71–1.CrossRefPubMedPubMedCentral Chung SS, Kim E, Park JH, Chung YR, Lito P, Teruya-Feldstein J, et al. Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Sci Transl Med. 2014;6:238ra71–1.CrossRefPubMedPubMedCentral
14.
go back to reference Arcaini L, Zibellini S, Boveri E, Riboni R, Rattotti S, Varettoni M, et al. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood. 2012;119:188–91.CrossRefPubMed Arcaini L, Zibellini S, Boveri E, Riboni R, Rattotti S, Varettoni M, et al. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood. 2012;119:188–91.CrossRefPubMed
15.
go back to reference Tiacci E, Schiavoni G, Forconi F, Santi A, Trentin L, Ambrosetti A, et al. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood. 2012;119:192–5.CrossRefPubMed Tiacci E, Schiavoni G, Forconi F, Santi A, Trentin L, Ambrosetti A, et al. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood. 2012;119:192–5.CrossRefPubMed
16.
go back to reference Ide M, Koba S, Sueoka-Aragane N, Sato A, Nagano Y, Inoue T, et al. Mutation profile of B-Raf gene analyzed by fully automated system and clinical features in japanese melanoma patients. Pathol Oncol Res. 2017;23:181–8.CrossRefPubMed Ide M, Koba S, Sueoka-Aragane N, Sato A, Nagano Y, Inoue T, et al. Mutation profile of B-Raf gene analyzed by fully automated system and clinical features in japanese melanoma patients. Pathol Oncol Res. 2017;23:181–8.CrossRefPubMed
17.
go back to reference Tanaka R, Kuroda J, Stevenson W, Ashihara E, Ishikawa T, Taki T, et al. Fully automated and super-rapid system for the detection of JAK2V617F mutation. Leuk Res. 2008;32:1462–7.CrossRefPubMed Tanaka R, Kuroda J, Stevenson W, Ashihara E, Ishikawa T, Taki T, et al. Fully automated and super-rapid system for the detection of JAK2V617F mutation. Leuk Res. 2008;32:1462–7.CrossRefPubMed
18.
go back to reference Okada K, Kunitomi A, Sakai K, Muranushi H, Okamoto Y, Tsukamoto T, et al. Hairy cell leukemia with systemic lymphadenopathy: detection of BRAF mutations in both lymph node and peripheral blood specimens. Intern Med. 2015;54:1397–402.CrossRefPubMed Okada K, Kunitomi A, Sakai K, Muranushi H, Okamoto Y, Tsukamoto T, et al. Hairy cell leukemia with systemic lymphadenopathy: detection of BRAF mutations in both lymph node and peripheral blood specimens. Intern Med. 2015;54:1397–402.CrossRefPubMed
19.
go back to reference Tiacci E, Park JH, De Carolis L, Chung SS, Broccoli A, Scott S, et al. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med. 2015;373:1733–47.CrossRefPubMedPubMedCentral Tiacci E, Park JH, De Carolis L, Chung SS, Broccoli A, Scott S, et al. Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. N Engl J Med. 2015;373:1733–47.CrossRefPubMedPubMedCentral
20.
go back to reference Samuel J, Macip S, Dyer MJS. Efficacy of vemurafenib in hairy-cell leukemia. N Engl J Med. 2014;370:286–8.CrossRefPubMed Samuel J, Macip S, Dyer MJS. Efficacy of vemurafenib in hairy-cell leukemia. N Engl J Med. 2014;370:286–8.CrossRefPubMed
21.
go back to reference Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med. 2012;366:2038–40.CrossRefPubMed Dietrich S, Glimm H, Andrulis M, von Kalle C, Ho AD, Zenz T. BRAF inhibition in refractory hairy-cell leukemia. N Engl J Med. 2012;366:2038–40.CrossRefPubMed
22.
go back to reference Suzuki SI, Matsusaka S, Hirai M, Shibata H, Takagi K, Mizunuma N, et al. A novel approach to detect KRAS/BRAF mutation for colon cancer: highly sensitive simultaneous detection of mutations and simple pre-treatment without DNA extraction. Int J Oncol. 2015;47:97–105.CrossRefPubMedPubMedCentral Suzuki SI, Matsusaka S, Hirai M, Shibata H, Takagi K, Mizunuma N, et al. A novel approach to detect KRAS/BRAF mutation for colon cancer: highly sensitive simultaneous detection of mutations and simple pre-treatment without DNA extraction. Int J Oncol. 2015;47:97–105.CrossRefPubMedPubMedCentral
23.
go back to reference Hashimoto Y, Tsukamoto N, Nakahashi H, Yokohama A, Saitoh T, Handa H, et al. Hairy cell leukemia-related disorders consistently show low CD27 expression. Pathol Oncol Res. 2009;15:615–21.CrossRefPubMed Hashimoto Y, Tsukamoto N, Nakahashi H, Yokohama A, Saitoh T, Handa H, et al. Hairy cell leukemia-related disorders consistently show low CD27 expression. Pathol Oncol Res. 2009;15:615–21.CrossRefPubMed
24.
go back to reference Ruiz-Argüelles GJ, Cantú-Rodríguez OG, Gómez-Almaguer D, Certes-Franco J, Góngora-Biachi RA, Pizzuto J, et al. Hairy cell leukemia is infrequent in Mexico and has a geographic distribution. Am J Hematol. 1996;52:316–8.CrossRefPubMed Ruiz-Argüelles GJ, Cantú-Rodríguez OG, Gómez-Almaguer D, Certes-Franco J, Góngora-Biachi RA, Pizzuto J, et al. Hairy cell leukemia is infrequent in Mexico and has a geographic distribution. Am J Hematol. 1996;52:316–8.CrossRefPubMed
25.
go back to reference Au WY, Kwong YL, Ma SK, Mak YK, Wong KF, Lei KI, et al. Hairy cell leukemia in Hong Kong Chinese: a 12-year retrospective survey. Hematol Oncol. 2000;18:155–9.CrossRefPubMed Au WY, Kwong YL, Ma SK, Mak YK, Wong KF, Lei KI, et al. Hairy cell leukemia in Hong Kong Chinese: a 12-year retrospective survey. Hematol Oncol. 2000;18:155–9.CrossRefPubMed
26.
go back to reference Kao H-W, Dunn P, Kuo M-C, Shih L-Y, Lin T-L, Wu J-H, et al. Classical hairy cell leukemia and its variant: a 17-year retrospective survey in Taiwan Chinese. Acta Haematol. 2011;126:186–93.CrossRefPubMed Kao H-W, Dunn P, Kuo M-C, Shih L-Y, Lin T-L, Wu J-H, et al. Classical hairy cell leukemia and its variant: a 17-year retrospective survey in Taiwan Chinese. Acta Haematol. 2011;126:186–93.CrossRefPubMed
27.
go back to reference Tamura K, Sawada H, Izumi Y, Fukuda T, Utsunomiya A, Ikeda S, et al. Chronic lymphocytic leukemia (CLL) is rare, but the proportion of T-CLL is high in Japan. Eur J Haematol. 2001;67:152–7.CrossRefPubMed Tamura K, Sawada H, Izumi Y, Fukuda T, Utsunomiya A, Ikeda S, et al. Chronic lymphocytic leukemia (CLL) is rare, but the proportion of T-CLL is high in Japan. Eur J Haematol. 2001;67:152–7.CrossRefPubMed
28.
go back to reference Chihara D, Ito H, Matsuda T, Shibata A, Katsumi A, Nakamura S, et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol. 2014;164:536–45.CrossRefPubMed Chihara D, Ito H, Matsuda T, Shibata A, Katsumi A, Nakamura S, et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol. 2014;164:536–45.CrossRefPubMed
29.
go back to reference Robbins BA, Ellison DJ, Spinosa JC, Carey CA, Lukes RJ, Poppema S, et al. Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood. 1993;82:1277–87.PubMed Robbins BA, Ellison DJ, Spinosa JC, Carey CA, Lukes RJ, Poppema S, et al. Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood. 1993;82:1277–87.PubMed
30.
go back to reference Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ. VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood. 2009;114:4687–95.CrossRefPubMedPubMedCentral Arons E, Suntum T, Stetler-Stevenson M, Kreitman RJ. VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood. 2009;114:4687–95.CrossRefPubMedPubMedCentral
31.
go back to reference Waterfall JJ, Arons E, Walker RL, Pineda M, Roth L, Killian JK, et al. High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias. Nat Genet. 2014;46:8–10 (Nature Publishing Group).CrossRefPubMed Waterfall JJ, Arons E, Walker RL, Pineda M, Roth L, Killian JK, et al. High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias. Nat Genet. 2014;46:8–10 (Nature Publishing Group).CrossRefPubMed
32.
go back to reference Shtivelman E, Davies MQa, Hwu P, Yang J, Lotem M, Oren M, et al. Pathways and therapeutic targets in melanoma. Oncotarget. 2014;5:1701–52.PubMedPubMedCentral Shtivelman E, Davies MQa, Hwu P, Yang J, Lotem M, Oren M, et al. Pathways and therapeutic targets in melanoma. Oncotarget. 2014;5:1701–52.PubMedPubMedCentral
33.
go back to reference Kawazoe A, Shitara K, Fukuoka S, Kuboki Y, Bando H, Okamoto W, et al. A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. BMC Cancer. 2015;15:258–66.CrossRefPubMedPubMedCentral Kawazoe A, Shitara K, Fukuoka S, Kuboki Y, Bando H, Okamoto W, et al. A retrospective observational study of clinicopathological features of KRAS, NRAS, BRAF and PIK3CA mutations in Japanese patients with metastatic colorectal cancer. BMC Cancer. 2015;15:258–66.CrossRefPubMedPubMedCentral
34.
go back to reference Badalian-Very G, Vergilio J. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116:6–8.CrossRef Badalian-Very G, Vergilio J. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116:6–8.CrossRef
35.
go back to reference Haroche J, Charlotte F, Arnaud L, Von Deimling A, Hélias-rodzewicz Z, Hervier B, et al. High prevalence of BRAF V600E mutations in Erdheim–Chester disease but not in other non-Langerhans cell histiocytoses brief report high prevalence of BRAF V600E mutations in Erdheim–Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012;120:2700–3.CrossRefPubMed Haroche J, Charlotte F, Arnaud L, Von Deimling A, Hélias-rodzewicz Z, Hervier B, et al. High prevalence of BRAF V600E mutations in Erdheim–Chester disease but not in other non-Langerhans cell histiocytoses brief report high prevalence of BRAF V600E mutations in Erdheim–Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012;120:2700–3.CrossRefPubMed
36.
go back to reference Szturz P, Hlavatý L, Prášek J, Dvořáková D. Erdheim–Chester disease and Schnitzler syndrome: so near, and yet so far. Int J Hematol. 2013;98:379–81.CrossRefPubMed Szturz P, Hlavatý L, Prášek J, Dvořáková D. Erdheim–Chester disease and Schnitzler syndrome: so near, and yet so far. Int J Hematol. 2013;98:379–81.CrossRefPubMed
37.
go back to reference Haroche J, Cohen-Aubart F, Emile JF, Arnaud L, Maksud P, Charlotte F, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim–Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121:1495–500.CrossRefPubMed Haroche J, Cohen-Aubart F, Emile JF, Arnaud L, Maksud P, Charlotte F, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim–Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121:1495–500.CrossRefPubMed
Metadata
Title
Identification of the BRAF V600E mutation in Japanese patients with hairy cell leukemia and related diseases using a quenching probe method
Authors
Hidekazu Itamura
Masaru Ide
Akemi Sato
Naoko Sueoka-Aragane
Eisaburo Sueoka
Aya Nishida
Taro Masunari
Sadao Aoki
Jun Takizawa
Junji Suzumiya
Shinya Kimura
Publication date
01-10-2018
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 4/2018
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-018-2506-3

Other articles of this Issue 4/2018

International Journal of Hematology 4/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine